Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer

Imunon, Inc.

2024-Q3 EPS reported -$1.39

Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.
Cash, investments of $10.3M; expects to fund operations into Q3 2025.
OVATION 2 topline: 11.1-month OS improvement, hazard ratio 0.74 in ITT; 15.7-month OS in per-protocol.
Plan 500-patient Phase 3 study start Q1 2025; End-of-Phase 2 FDA meeting later in November 2024.
Raised $10M gross proceeds in July 2024 registered direct offering; added General Counsel and SVP of Operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.